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Lescol in Renal Transplant (ALERT) trial.
Background. Hyperlipidemia is a risk factor for long-term re-
nal transplant dysfunction, but no prospective clinical trials have
investigated the effects of statin treatment on graft function in
renal transplant recipients. The aim of the present study was to
evaluate the effect of fluvastatin on long-term renal transplant
function and development of chronic allograft nephropathy in
the ALERT (Assessment of Lescol in Renal Transplantation)
study.
Methods. ALERT was a randomized, double-blind, placebo-
controlled study of the effect of fluvastatin, 40 mg and 80 mg
daily, in renal transplant recipients. Patients were randomized
to receive either fluvastatin (N = 1050) or placebo (N = 1052)
and followed for five to six years. Renal end points included
graft loss or doubling of serum creatinine or death; glomerular
filtration rate (GFR) was also measured during follow-up in a
subset of patients (N = 439).
Results. There were 283 patients (13.5%) with graft loss,
mainly due to chronic rejection (82%), yielding an annual rate
of 2.4%. Fluvastatin treatment significantly lowered mean low-
density lipoprotein (LDL)-cholesterol levels by 32% (95% CI
−33 to −30) compared with placebo, but had no significant ef-
fect on the incidence of renal graft loss or doubling of serum
creatinine, or decline in GFR throughout follow-up in the whole
study population. Neither was any treatment effect by fluvas-
tatin found in any of the subgroups analyzed.
Conclusion. Fluvastatin treatment significantly improves
lipid values in renal transplant recipients but has no effect on
graft loss or doubling of serum creatinine.
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One of the leading causes of long-term failure of trans-
planted organs is chronic rejection (CR) or chronic al-
lograft nephropathy (CAN) [1–4]. Various studies have
shown that beyond one year post-transplantation there
is a 3% to 4% annual loss of transplanted kidneys due
to CAN. In transplanted hearts and kidneys, signs of CR
were found in 40% to 60% of transplants at five years’
post-transplantation.
The pathogenesis of CAN involves a combination of
immunologic and nonimmunologic factors [5, 6]. The
alloreaction participates in the development of CAN
mainly through activated monocytes and macrophages.
These cells have the ability to synthesize and secrete
cytokines, and, more importantly, growth factors, which
act on smooth muscle cells and fibroblasts to stimulate
proliferation and synthesis of connective tissue proteins
[7–10]. These effects will propel the CAN process [2, 3].
Several nonimmunologic risk factors have also been
shown to exert an impact on the CAN process [6]. These
factors include ischemia-reperfusion damage [9, 11–14],
hypertension [15–17], hypercholesterolemia [18–20], and
obesity. Lipoprotein abnormalities have been reported
to be common among transplant patients, particularly
during the use of cyclosporine-based immunosuppres-
sive protocols [21]. Hyperlipidemia, and in particular
hypercholesterolemia, has also been associated with
progressive deterioration of renal transplant function,
and has been considered to be a risk factor for the
development of CAN [18–20]. Indeed, lipid-lowering
treatment with pravastatin [22] or simvastatin [23] has
been administered to heart transplant patients, and was
shown to have a beneficial effect on the development
of transplant atherosclerosis. HMG-CoA reductase
inhibitors have well-documented effects on the levels of
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low-density lipoprotein cholesterol (LDL-cholesterol)
and high-density lipoprotein cholesterol (HDL-
cholesterol), as well as on triglyceride levels. Moreover,
statins also act as inhibitors of smooth muscle cell
proliferation, synthesis of extracellular matrix protein,
and renal mesangial cell proliferation in vitro [24].
We therefore carried out a renal transplant function
study within the ALERT trial. The objectives of the re-
nal study were to evaluate the effect of fluvastatin on
prespecified end points of renal transplant function and
graft loss, based on the hypothesis that the cholesterol-
lowering effect of fluvastatin, and the inhibitory effect
of the drug on smooth muscle cell proliferation, would
improve long-term graft function.
METHODS
The ALERT study design and baseline data have
been described previously [28]. Briefly, ALERT recruited
2102 renal transplant recipients from nephrology units
and transplant clinics in Northern and Central Europe
(Belgium, Denmark, Finland, Germany, Norway, Swe-
den, Switzerland, United Kingdom) and Canada [29].
Patients
Male and female patients, aged 30 to 75 years, who
had received a renal (or combined renal and pancreas)
transplant more than six months prior to randomization,
with stable graft function, and with a total serum choles-
terol concentration between 4.0 and 9.0 mmol/L (155 to
348 mg/dL) were recruited. Patients with a history of
myocardial infarction (MI) more than six months prior
to randomization could be enrolled if their total choles-
terol levels ranged from 4.0 to 7.0 mmol/L (155 to 270
mg/dL). Narrower total cholesterol ranges for inclusion
were used, if necessary, to satisfy the requirements of lo-
cal ethics committees. Patients were excluded if they were
on statin therapy, had familial hypercholesterolemia, or
had experienced an acute rejection episode in the three
months prior to randomization. In addition, patients with
a predicted life expectancy of less than one year were ex-
cluded. The primary causes of renal failure were chronic
glomerulonephritis 35%, polycystic kidney disease 15%,
diabetic nephropathy 13%, pyelonephritis or interstitial
nephritis 12%, and hypertensive renal disease 5%.
The study adhered to the International Conference on
Harmonization guidelines for Good Clinical Practice and
was in accordance with the Declaration of Helsinki. All
participants provided written informed consent, and the
ethics committee at each participating center approved
the trial.
Treatment and follow-up
Patients were initially randomized to receive either
fluvastatin, 40 mg/day (Lescol; Novartis Pharma AG,
Basel, Switzerland), or matching placebo. After approx-
imately two years, the dose of study drug was doubled
for both groups after obtaining written informed patient
consent. The dose increase was implemented on the rec-
ommendation of the independent Data and Safety Moni-
toring Board [28], and was based on emerging safety data
and clinical outcome trials published after the design of
ALERT that provided additional information on the re-
lationship between achieved LDL-cholesterol levels and
reduction of CV events.
Trial procedure
Patients were followed up for a minimum of five and
a maximum of six years. Study patients were seen at
1.5 months following randomization, and at six-month
intervals thereafter. At each visit, laboratory measures,
including fasting lipids (serum total cholesterol, LDL-
cholesterol, HDL-cholesterol), serum creatinine, crea-
tine kinase (CK), and hepatic enzymes were assessed at
a central laboratory (CRL; Medinet, Breda, The Nether-
lands). No additional lipid analyses were permitted in
the local setting, and the investigators were blinded to
patients’ lipid levels unless informed by the central labo-
ratory of predefined high values.
In addition to the above, baseline data also included
demographic data related to renal transplantation, such
as HLA-DR mismatches, cold ischemia time, donor age,
and the presence of panel-reactive antibodies. Baseline
data on metabolic and hemodynamic factors were also
included. Graft losses, increases in serum creatinine (in
particular, doubling of serum creatinine), and urinary
excretion of protein or albumin were evaluated for the
whole study population.
Four hundred thirty-nine patients were included in
a separate renal substudy provided that they were on
cyclosporine treatment and had a glomerular filtration
rate (GFR) >20 mL/min. GFR measurements, Cockroft-
Gault calculation of renal clearance, and urinary protein
excretion were all measured at baseline, and at 18, 36,
and 60 months during follow-up. GFR methods used in
the study were Cr-EDTA clearance or iohexol clearance,
or any other approved GFR marker according to the local
traditions at the respective centers of the study.
End point definition
Prespecified secondary end points in the ALERT study
were graft loss, graft loss or doubling of serum creatinine,
and graft loss or doubling of serum creatinine or patient
death during the five- to six-year follow-up period.
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Table 1. Characteristics of intention to treat population at baseline
Fluvastatin Placebo
(N = 1050)∗ (N = 1052)∗
Age years 49.5 (10.9) 50.0 (11.0)
Male N (%) 701 (66.8) 686 (65.2)
Diastolic BP mm Hg 85.6 (10.1) 85.6 (10.0)
Systolic BP mm Hg 143.8 (18.7) 144.0 (19.1)
BMI kg/m2 25.8 (4.4) 25.8 (4.6)
Total cholesterol mmol/L 6.4 (1.1) 6.5 (1.1)
LDL cholesterol mmol/L 4.1 (1.0) 4.1 (1.0)
HDL cholesterol mmol/L 1.3 (0.5) 1.4 (0.4)
Triglycerides mmol/L 2.2 (1.2) 2.2 (1.5)
Hypertension N (%) 798 (76) 777 (74)
Smoking (current) N (%) 204 (19.4) 185 (17.6)
Smoking (previous) N (%) 385 (36.7) 358 (34.0)
Diabetes N (%) 197 (18.8) 199 (18.9)
Concomitant immunosuppressive medications N (%)a
Cyclosporine 1050 (100) 1052 (100)
Azathioprine 684 (65.1) 680 (64.6)
Prednisolone 851 (81.0) 848 (80.6)
Cyclophosphamide 9 (0.9) 10 (1.0)
Mycophenolate mofetil (MMF) 167 (15.9) 159 (15.1)
Other 198 (18.9) 224 (21.3)
Concomitant CV medications N (%)a
Any CV drug 1001 (95.3) 999 (95.0)
Beta-blockers 649 (61.8) 627 (59.6)
Calcium antagonists 729 (69.4) 738 (70.2)
ACE inhibitors or 520 (49.5) 529 (50.3)
AT1-receptor blockers
Diuretics 590 (56.2) 573 (54.5)
Alpha blockers 176 (16.8) 170 (16.2)
Other 316 (30.1) 373 (35.5)
Abbreviations are: ACE, angiotensin-converting enzyme; AT1, angiotensin II
type 1 receptor; BP, blood pressure; BMI, body mass index; CV, cardiovascular;
HDL, high density lipoprotein; LDL, low density lipoprotein. Data are expressed
as mean (SD) unless otherwise indicated.
aTaken at least once during the study.
Subgroup analysis
Potential risk factors for reaching renal end points were
compared between the actively treated group (fluvas-
tatin) and the placebo group at baseline. There were no
differences between the two groups with regard to poten-
tially important risk factors for reaching renal end points
(Tables 1 and 2).
Subgroup analysis of the treatment effect was carried
out with respect to anticipated risk factors and baseline
characteristics, with the effect of fluvastatin treatment be-
ing studied in patients with or without the respective risk
factor. For risk factors that were continuous variables,
the treatment effect was analyzed by dividing patients
into those above or below the median value of the risk
factor.
Sample size and statistical methods
The number of patients needed in the core study, which
focused on cardiovascular events during follow-up, was
2050 patients, and 2102 patients were randomized. This is
also the population in which renal end points were cap-
tured and treatment effects by fluvastatin were assessed.
It could be calculated that for the composite renal end
Table 2. Renal transplant characteristics of intention to treat
population at baseline
Fluvastatin Placebo
(N = 1050) (N = 1052)
First transplantation N (%) 894 (85.1) 900 (85.6)
Recipient age at last transplantation years 44.3 (11.3) 44. 8 (11.4)
Time since last transplantation years 5.2 (3.4) 5.2 (3.4)
Rejections since last transplantation N (%) 454 (43.2) 448 (42.6)
Cold ischemia time hours 19.8 (7.6) 19.7 (7.9)
Delayed graft function (DGF) 180 (17.1) 185 (17.6)
Donor age years 40.2 (15.2) 40.9 (15.4)
No HLA-DR mismatches N (%) 336 (32.1) 326 (31.0)
Panel-reactive antibodies positive N (%) 163 (15.5) 164 (15.6)
Treatment for CMV N (%) 148 (14.1) 138 (13.1)
Total months on renal replacement therapy 88.5 (56.5) 88.8 (58.3)
Type of last transplantation N (%)
Live donor 240 (22.9) 229 (21.8)
Cadaveric donor 809 (77.0) 822 (78.1)
Serum creatinine lmol/L 147 (54.4) 143 (51.0)
Urinary protein g/24h 0.5 (1.4) 0.4 (0.7)
[N = 753] [N = 770]
Urinary albumin g/24h 0.3 (0.8) 0.2 (0.5)
[N = 298] [N = 270]
Creatinine clearance mL/min 60.2 (20.8) 60.3 (20.7)
[N = 1007] [N = 1003]
Data are expressed as mean (SD) unless otherwise indicated.
point with 80% power we would miss to detect effect sizes
below 20% at the 5% significance level. GFR measure-
ments and Cockroft-Gault calculations of renal clearance
were made in 439 patients.
Demographic and clinical baseline characteristics were
compared by Fisher exact test, the Mann-Whitney U test,
or paired t test, according to the respective variable. The
efficacy analysis was based on a log-rank test. Life ta-
ble curves were generated by the Kaplan-Meier method.
The Cox proportional hazards model and the Cochran-
Mantel-Haenszel test were used to assess risk reduction
and to compare the incidence of end points. All secondary
end points were tested using a 5% level of significance.
RESULTS
Baseline characteristics
Between June 1996 and October 1997, a total of 2102
patients were randomly assigned to receive fluvastatin,
40 mg/day (N = 1050) or placebo (N = 1052); these pa-
tients formed the intent-to-treat (ITT) population of the
study. The groups were well balanced with regard to base-
line demographic and clinical characteristics, and trans-
plantation and renal characteristics (Tables 1 and 2) [25].
Patients in both groups were primarily male, with a
mean age of 50 years. The major causes of renal failure
for both groups were glomerulonephritis and polycystic
kidney disease. At baseline, approximately three quarters
of patients in both groups had hypertension, and one fifth
had a history of diabetes.
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The mean duration of follow-up was 5.1 years. The dose
of study medication was doubled in 65% of patients in
both groups after a mean follow-up duration of 2.8 years.
Over the duration of study, 8% and 15% of patients in the
fluvastatin and placebo groups, respectively, took other
lipid-lowering treatments (primarily statins).
Concurrent medications taken by patients during the
study were similar in both groups. All patients who
entered the study received cyclosporine; 81% received
steroids, 65% received azathioprine, and 16% received
mycophenolate mofetil (MMP). Beta-blockers and cal-
cium antagonists were the most frequently used cardio-
vascular drugs. Angiotensin-converting enzyme (ACE)
inhibitors or AT1-receptor blockers were used in 50%
of patients. The use of any cardiovascular drug over
the total duration of follow-up was 95% in both groups
(Table 1).
Baseline demographic data were similar in the two
treatment groups (Table 2).
Mean time since last transplantation was 5.5 years; 85%
of cases were single first-time transplantations, 24% of
patients received transplants from a live donor, and 32%
of all patients were transplanted without any HLA-DR
mismatches. Mean creatinine clearance was 60 mL/min
at inclusion. Mean urinary proteinuria was 450 mg/24h,
and mean albuminuria was 250 mg/24h at baseline.
Incidence of end points
There was a linear increase in the number of renal end
points during the course of the study. During the course
of the study, 283 patients had experienced a graft loss, 348
patients had a graft loss or doubling of serum creatinine,
and 544 patients had a graft loss or doubling of serum
creatinine or died. The causes of graft loss were chronic
rejection (N = 202), recurrent glomerulonephritis (N =
31), infection (N = 7), de novo glomerulonephritis
(N = 3), thrombosis (N = 2), and the rest unknown or not
reported—thus, a total rate of graft losses of 13.5%, or
an annual rate of 2.4%. Since 82% were due to reported
CR, this gives an annual rate of 2% of graft losses due to
CR in this population.
Effect of fluvastatin on lipid variables and renal
end points
As reported previously [25], fluvastatin treatment was
associated with a significant lowering of mean LDL-
cholesterol by 32% (95% CI −33 to −30; net difference
1.0 mmol/L) compared with placebo. Mean total choles-
terol and triglyceride levels also decreased significantly
in the fluvastatin group.
There was no significant difference between patients
treated with fluvastatin or placebo with regard to graft
losses, doubling of serum creatinine, or patient death.
Thus, no effect of fluvastatin on any of these renal end
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Fig. 1. Effect of fluvastatin treatment on renal end points in the As-
sessment of Lescol in Renal Transplant (ALERT) study. Kaplan-Meier
curves showing survival time free of (A) renal graft loss, (B) renal graft
loss or doubling of serum creatinine, or (C) renal graft loss or doubling
of serum creatinine or death, in renal transplant recipients randomized
to receive treatment with either fluvastatin or placebo in the ALERT
study.
points was observed (Fig. 1; Table 3). Neither was there
any effect on the slope of inverse creatinine during the
follow-up. The degree of proteinuria was neither re-
duced nor increased in the fluvastatin group compared
with the placebo group. There was no difference in the
development of GFR at 18, 36, and 60 months in the
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Table 3. Effect of fluvastatin treatment on incidence of renal end points in the ALERT study
Incidence
Fluvastatin Placebo
No. of patients with end points (N = 1050) (N = 1052) RR 95% CI P valuea
Graft loss 146 (13.9) 137 (13.0) 1.055 0.835, 1.334 0.6520
Graft loss or doubling of 183 (17.4) 165 (15.7) 1.102 0.892, 1.361 0.3693
serum creatinine
Graft loss or doubling of 276 (26.3) 268 (25.6) 1.02 0.86, 1.21 0.7893
serum creatinine or death
RR, relative risk; CI, confidence interval.
aP values were determined by the Cox-Wald test.
Table 4. Change in glomerular filtration rate during follow-up
Fluvastatin Placebo
(N = 222) (N = 217) P
Visit N Mean (SD) N Mean (SD) Difference value
GFR mL/min/1.73 m2
Baseline 222 52.9 (21.4) 217 52.1 (20.0) −0.8
18 months 191 51.5 (20.5) 185 49.3 (19.4) −2.1 0.7571
36 months 178 50.5 (21.7) 172 49.6 (21.7) −0.9 0.7545
60 months 130 46.0 (22.2) 114 47.1 (20.0) 1.0 0.8843
GFR by Cockcroft-Gault formula mL/min/1.73 m2
Baseline 218 64.7 (24.4) 208 64.3 (19.3) −0.8
36 months 177 55.6 (19.1) 169 56.6 (18.8) 1.0 0.6235
60 months 128 55.2 (21.9) 110 59.2 (20.2) 4.0 0.5156
GFR, glomerular filtration rate.
fluvastatin group compared with the placebo group
throughout follow-up (Table 4). Importantly, lipids were
not risk factors for reaching renal end points in this study.
Subgroup analysis of the treatment effect was carried
out with respect to baseline characteristics and potential
risk factors, but no treatment effects could be demon-
strated in any of the analyzed subgroups. In patients with
a well-controlled blood pressure (BP) (i.e., systolic BP
<130 mm Hg), there was a trend toward reduction in
the incidence of renal end points (Table 5). Notably,
there was no difference observed among patients re-
ceiving treatment with ACE inhibitors or AT1-receptor
blockers, compared with those receiving other antihyper-
tensive agents. No treatment effects of fluvastatin were
observed either in patients receiving or not receiving
treatment with MMF.
DISCUSSION
ALERT is the largest interventional trial undertaken
in renal transplant patients, and the first prospective con-
trolled trial to study cardiac and renal outcomes in this
population. The main ALERT study showed that treat-
ment with fluvastatin, 40 mg and 80 mg daily, signif-
icantly lowered mean LDL-cholesterol levels by 32%
(95% CI −33 to −30) compared with placebo, a re-
duction that is comparable to those seen in other ma-
jor statin outcome trials [25]. Fluvastatin treatment also
significantly lowered mean total cholesterol and triglyc-
eride levels compared with placebo. Two thirds of patients
in the fluvastatin group achieved total cholesterol levels
<5 mmol/L, and three quarters of the fluvastatin-treated
patients achieved LDL-cholesterol levels <3 mmol/L,
meeting the targets of published guidelines for the pre-
vention of coronary heart disease [26]. Fluvastatin treat-
ment in ALERT significantly reduced the risk of fatal
and nonfatal definite cardiac events, resulting in a 35%
risk reduction of cardiac death or definite nonfatal MI in
the fluvastatin group (RR 0.65; 95% CI 0.48–0.88, P =
0.005). Importantly, the incidence of adverse events with
fluvastatin treatment was similar to that of placebo, re-
flecting the advantage that fluvastatin has over other
statins in transplant recipients as a result of its low risk of
interactions with calcineurin inhibitors [27, 28]. The re-
sults of this analysis investigating renal end points within
the ALERT trial show that fluvastatin treatment had no
effect on the incidence of graft loss, doubling of serum
creatinine, or death compared with placebo in this study
population.
The absence of any effect of fluvastatin treatment on
the prespecified renal end points of graft loss or dou-
bling of serum creatinine in the present ALERT trial
was somewhat unexpected. CAN, which is the most
common cause of late graft failure, shares pathophys-
iologic mechanisms with atherosclerosis, and has been
associated with hypercholesterolemia [19, 20]. Thus, pro-
liferation of smooth muscle cells and accumulation of
extracellular matrix proteins are principal histopatho-
logic features seen in glomerular injury, and show marked
similarity with the cellular and molecular events that
occur in atherosclerosis. The pleiotropic effects of flu-
vastatin, which include decreased expression of adhesion
molecules, prevention of low-density lipoprotein oxida-
tion, and inhibition of smooth muscle cell proliferation
and migration [29], might therefore be expected to con-
tribute to delay or prevent allograft dysfunction.
The lack of effect of fluvastatin on the renal end
points investigated in the present study may reflect
the characteristics of the study population, which con-
sisted of long-term renal transplant survivors, whose
mean time from last transplantation was more than five
1554 Fellstro¨m et al: Fluvastatin and renal transplant function
Table 5. Subgroup analysis for reaching renal end point of graft loss or doubling of serum creatinine
Subgroup Placebo Fluvastatin RR (95% CI) P value
Transplant characteristic
Male 110/686 (16%) 129/701 (18.4%) 1.17 [0.91, 1.51] 0.2295
Female 55/366 (15.0%) 54/349 (15.5%) 0.91 [0.62, 1.34] 0.6292
Age (<49.3 years) 100/514 (19.5%) 108/528 (20.5%) 1.07 [0.81, 1.40] 0.6436
Age (≥49.3 years) 65/538 (12.1%) 75/522 (14.4%) 1.14 [0.82, 1.60] 0.4325
Donor age (<41.0 years) 47/489 (9.6%) 68/499 (13.6%) 1.36 [0.93, 1.98] 0.1101
Donor age (≥41.0 years) 111/539 (20.6%) 114/531 (21.5%) 1.06 [0.81, 1.38] 0.6649
Time after Tx (<4.5 years) 73/521 (14%) 76/522 (14.6%) 0.99 [0.72, 1.37] 0.9502
Time after Tx (≥4.5 years) 92/531 (17.3%) 107/527 (20.3%) 1.16 [0.87, 1.53] 0.3096
No HLA-DR mismatches 48/326 (14.7%) 48/336 (14.3%) 0.91 [0.61, 1.36] 0.6333
One 75/529 (14.2%) 87/510 (17.1%) 1.22 [0.89, 1.67] 0.2076
Two 34/159 (21.4%) 42/169 (24.9%) 1.16 [0.73, 1.83] 0.5352
Cardiovascular risk factors
Diabetes 33/199 (16.6%) 39/197 (19.8%) 1.19 [0.74, 1.91] 0.4807
No diabetes 132/853 (15.5%) 144/852 (16.9%) 1.07 [0.85, 1.36] 0.5507
Nonsmoker 77/508 (15.2%) 63/460 (13.7%) 0.82 [0.58, 1.14] 0.2328
Ex-smoker 42/358 (11.7%) 52/385 (16.6%) 1.46 [0.98, 2.16] 0.0629
Smoker 46/185 (24.9%) 58/204 (28.4%) 1.12 [0.75, 1.66] 0.5801
No hypertension 29/275 (10.5%) 37/252 (14.7%) 1.33 [0.82, 2.17] 0.2513
Hypertension 136/777 (17.5%) 146/798 (18.3%) 1.05 [0.83, 1.33] 0.6806
Renal function characteristic
Creatinine (<134 lmol/L) 37/517 (7.2%) 31/494 (6.3%) 0.85 [0.52, 1.38] 0.5055
Creatinine (≥134 lmol/L) 120/496 (24.2%) 146/521 (28.0%) 1.15 [0.90, 1.47] 0.2626
Albuminuria (<0.1 g/24h) 17/168 (10.1%) 9/187 (4.8%) 0.47 [0.21, 1.06] 0.0673
Albuminuria (≥0.1 g/24h) 32/102 (31.4%) 46/102 (45.1%) 1.41 [0.88; 2.24] 0.1517
Proteinuria (<0.2 g/24h) 30/371 (8.1%) 29/344 (8.4%) 1.09 (0.65, 1.81) 0.7552
Proteinuria (≥0.2 g/24h) 85/399 (21.3%) 99/409 (24%) 1.12 (0.84, 1.50) 0.4448
Lipid parameters
TC (<6.4 mmol/L) 82/497 (16.5%) 82/502 (16.3%) 1.02 [0.75, 1.39] 0.8844
TC (≥6.4 mmol/L) 75/516 (14.5%) 95/513 (18.5%) 1.24 [0.91, 1.68] 0.1714
LDL (<4.1 mmol/L) 74/492 (15%) 83/473 (17.5%) 1.25 [0.91, 1.71] 0.1674
LDL (≥4.1 mmol/L) 81/509 (15.9%) 91/527 (17.3%) 1.03 [0.76, 1.39] 0.8524
HDL (<1.3 mmol/L) 92/474 (19.4%) 102/485 (21.0%) 1.09 [0.82, 1.44] 0.5747
HDL (≥1.3 mmol/L) 64/536 (11.9%) 73/522 (14.0%) 1.15 [0.82, 1.61] 0.4318
TG (<1.9 mmol/L) 67/499 (13.4%) 75/481 (15.6%) 1.13 [0.81, 1.58] 0.4568
TG (≥1.9 mmol/L) 90/514 (17.5%) 102/534 (19.1%) 1.11 [0.84, 1.48] 0.4661
Blood pressure parameters
DBP (<80 mm Hg) 36/188 (20%) 25/183 (14%) 0.60 [0.36, 1.20] 0.058
DBP (>80 mm Hg) 129/868 (14.9%) 157/861 (18.2%) 1.16 [0.75, 1.83] 0.437
SBP (<130 mm Hg) 31/193 (16%) 21/198 (10.6%) 0.55 [0.31, 0.98] 0.044
SBP (≥130 mm Hg) 134/856 (15.6%) 164/847 (19%) 1.16 [0.77, 1.75] 0.371
Live donor 35/229 (15.3%) 36/240 (15.0%) 0.84 [0.52, 1.34] 0.4588
Cadaveric donor 129/822 (15.7%) 147/809 (18.2%) 1.19 [0.93, 1.50] 0.1598
Abbreviations are: DBP, diastolic blood pressure; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; SBP, systolic blood pressure;
TC, total cholesterol; TG, triglycerides; Tx, transplantation.
years prior to enrolment. Hence, many of the pathologic
processes that are known to lead to CAN would have
been well advanced in the ALERT patients before they
received fluvastatin. Although statin treatment has been
shown to improve outcomes and reduce graft vasculopa-
thy in cardiac transplant patients [22, 23], it is notable
that these studies initiated statin treatment early after
transplantation. However, subgroup analysis showed no
effect of fluvastatin either in patients included within 4.5
years of renal transplantation, or in patients included at
a later stage (>4.5 years after transplantation). In addi-
tion, there was no treatment effect related to the level of
renal function at inclusion. Neither were there any treat-
ment effects related to whether the patient was diabetic or
not. Most importantly, LDL- or total cholesterol were not
risk factors for reaching renal end points in the ALERT
population (not shown), and subgroup analysis with re-
gard to lipid values at baseline did not show any treat-
ment effects either. A trend toward beneficial effects of
fluvastatin was observed in patients with albuminuria
<100 mg/24h or with a well-controlled blood pressure.
None of the lipid parameters measured in this study
appeared to be related to the effect of fluvastatin on the
incidence of renal end points, which is in contrast
with previous reports indicating that lipids are risk fac-
tors for renal allograft [18–20, 30]. The commonly ac-
cepted hypothesis that lipoproteins are implicated in the
pathogenesis of glomerulosclerosis is supported by the
observation that patients with pretransplant hypercholes-
terolemia have an increased number of acute rejection
episodes, worse graft function, and more graft losses dur-
ing up to three years of follow-up [19]. These results
indicate that lipid abnormalities have marked deleteri-
ous effects on graft function within two to three years
of transplantation that would already have occurred in
the majority of ALERT patients before the study was
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initiated. This may provide an explanation for the ob-
served lack of influence of lipid parameters on renal end
points in the present study, and hence, the lack of effect of
fluvastatin on these end points. However, it should again
be noted that no treatment effect of fluvastatin was ob-
served either in patients included at an early stage after
renal transplantation (<4.5 years) or those included at a
later stage.
There was a trend toward beneficial effects of fluvas-
tatin in patients with well-controlled blood pressure (sys-
tolic BP <130 mm Hg) in the present study. In this patient
subgroup, graft loss or doubling of serum creatinine was
35% lower in patients treated with fluvastatin compared
to placebo (P < 0.044). It is well known that hyperten-
sion is a risk factor for the progression of chronic renal
failure [31], although hypertension may also occur as a
consequence of deteriorating graft function or acting as
risk factor for CAN [15–17]. It is possible that hyperten-
sion has such a strong impact on graft dysfunction that
statin treatment does not have any discernible effect un-
less blood pressure is well controlled.
CONCLUSION
The ALERT trial has established the benefits and
safety of fluvastatin treatment for the prevention of car-
diac morbidity and mortality in renal transplant recipi-
ents. The present analysis of the ALERT trial showed no
significant effect of fluvastatin on the prespecified renal
end points of renal graft loss or doubling of serum cre-
atinine. Thus, early introduction of statin therapy after
renal transplantation can be recommended for cardiac
protection, but not for renal protection in general.
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